首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   270篇
  免费   29篇
  国内免费   27篇
耳鼻咽喉   1篇
儿科学   19篇
妇产科学   3篇
基础医学   39篇
口腔科学   18篇
临床医学   49篇
内科学   73篇
皮肤病学   11篇
神经病学   5篇
特种医学   25篇
外科学   21篇
综合类   18篇
预防医学   7篇
药学   14篇
中国医学   1篇
肿瘤学   22篇
  2022年   3篇
  2021年   3篇
  2020年   1篇
  2019年   3篇
  2018年   5篇
  2017年   7篇
  2016年   7篇
  2015年   9篇
  2014年   6篇
  2013年   12篇
  2012年   8篇
  2011年   4篇
  2010年   12篇
  2009年   12篇
  2008年   5篇
  2007年   13篇
  2006年   7篇
  2005年   15篇
  2004年   5篇
  2003年   4篇
  2002年   7篇
  2001年   12篇
  2000年   4篇
  1999年   8篇
  1998年   22篇
  1997年   18篇
  1996年   18篇
  1995年   13篇
  1994年   14篇
  1993年   3篇
  1992年   3篇
  1991年   3篇
  1990年   3篇
  1989年   8篇
  1988年   5篇
  1987年   6篇
  1986年   14篇
  1985年   4篇
  1982年   2篇
  1981年   2篇
  1980年   1篇
  1978年   4篇
  1977年   4篇
  1976年   4篇
  1975年   3篇
排序方式: 共有326条查询结果,搜索用时 15 毫秒
101.
Chan  FK  Ching  JY  Hung  LC  齐文安 《英国医学杂志》2005,8(6):372-373
问题:在有阿司匹林诱发溃疡出血史的患者中,用氯毗格雷预防溃疡出血复发,是否不次于小剂量阿司匹林加埃索美拉唑?[编者按]  相似文献   
102.
103.
104.

Introduction

Inhaled mannitol has beneficial effects on lung function, mucociliary clearance, quality of life and sputum properties. This trial examined the efficacy of inhaled mannitol in children with cystic fibrosis (CF).

Methods

The efficacy of inhaled mannitol in children with CF aged 6–17 years was assessed in a phase 2, randomised, placebo-controlled crossover study. Subjects were randomly assigned to mannitol 400 mg every 12 h or matching placebo for 8 weeks, followed by an 8 week washout and an 8 week period with the alternate treatment. The primary endpoint was the absolute change from baseline in ppFEV1 (percent predicted FEV1).

Results

A total of 92 subjects were studied, with a mean age of 12 years and mean baseline ppFEV1 of 72.2%. During mannitol treatment ppFEV1 was 3.42% (p = 0.004) higher compared to placebo or a 4.97% (p = 0.005) relative difference; relative change from baseline FEF25-75 was 10.52% (p = 0.013). During mannitol treatment, acute post-treatment sputum weight was higher (p = 0.012). In pre-specified subgroups (rhDNase use, age, and disease severity), the treatment differences consistently favoured mannitol. The most common AEs were cough and pulmonary exacerbations. Pulmonary exacerbation AEs were approximately 30% lower in the mannitol group.

Conclusions

In children with CF, inhaled mannitol was associated with significant improvements in lung function and sputum weight, irrespective of rhDNase use, age or disease severity. Inhaled mannitol was well tolerated and was associated with a reduced incidence of pulmonary exacerbation AEs. (Clinical Trials.Gov: NCT 01883531)  相似文献   
105.
106.
Two new human myeloma cell lines have been established from a 36-year- old woman with refractory IgG kappa multiple myeloma in whom bilateral malignant pleural effusions developed. The malignant plasma cells from each effusion were set up in a liquid culture using an L-15 medium containing catalase, glutathione, selenous acid, ascorbic acid, insulin, transferrin, additional glutamine hydrocortisone, and 2- mercaptoethanol and designated as M-3 medium. Two IgG kappa cell lines, LB -831 and LB-832, were established and proved to be Epstein-Barr virus negative using the internal repeat sequence DNA probe. Characteristic plasma cell morphology was evident by light and electron microscopy. Immunotyping revealed an IgG kappa , B1+, B2-, Ia (HLA- DR)+, CALLA+ phenotype for each cell line as well as for the original pleural fluid and bone marrow myeloma cells. The supernatants also contained IgG kappa, beta 2 microglobulin, and large amounts of osteoclast-activating factor (indicating bone-resorbing activity). Cytogenetic analysis of the LB-831 cell line revealed a nearly triploid highly abnormal karyotype with numerous clonal chromosomal abnormalities involving chromosomes 1, 3, 5, 7, 13, and 15; several structurally abnormal marker chromosomes; and a putative homogeneously staining region on chromosome 7p at band p22. Analysis of the LB-832 cell line revealed several additional clonal abnormalities. These additional cytogenetic changes suggest that in vivo sequential clonal evolution occurred in this patient. Therefore, two new but related cell lines have been established, which should prove useful for further biological studies.  相似文献   
107.
108.
Immunopathogenesis and therapy of cutaneous T cell lymphoma   总被引:9,自引:0,他引:9       下载免费PDF全文
Cutaneous T cell lymphomas (CTCLs) are a heterogenous group of lymphoproliferative disorders caused by clonally derived, skin-invasive T cells. Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common types of CTCLs and are characterized by malignant CD4(+)/CLA(+)/CCR4(+) T cells that also lack the usual T cell surface markers CD7 and/or CD26. As MF/SS advances, the clonal dominance of the malignant cells results in the expression of predominantly Th2 cytokines, progressive immune dysregulation in patients, and further tumor cell growth. This review summarizes recent insights into the pathogenesis and immunobiology of MF/SS and how these have shaped current therapeutic approaches, in particular the growing emphasis on enhancement of host antitumor immune responses as the key to successful therapy.  相似文献   
109.

Background  

Several humoral immune factors are responsible for a successful pregnancy. There are a few studies, which demonstrate the role of antipaternal cytotoxic antibodies (APCA) and mixed lymphocyte reaction blocking factor (MLR-Bf) in the maintenance of pregnancy. However, these factors have not been studied in women with history of recurrent spontaneous abortion (RSA). We designed this study to review the role of APCA and MLR-Bf in normal pregnancy as well as in women with a history of RSA.  相似文献   
110.
时岩  孙林潮  高天文 《医学争鸣》1999,20(9):826-826
0 引言 东方人接受皮肤磨削术治疗后色素沉着的发生率明显高于西方人.尽管采用了目前被认为是最适宜亚洲人的铒激光治疗,色素沉着仍可发生.因此,在实施该手术治疗前应严格掌握适应证,制定严密的预防治疗措施,使得色素沉着的发生率降至最低,从而最大限度的防止医疗纠纷的发生.1 对象和方法1.1 对象 21例患者,男2例,女19例,平均年龄29.2(08~48)岁.皱纹祛除8例,浅表疤痕7例,浅咖啡斑、黑子5例,不良纹眉1例.铒激光其它适应证:①老年斑;②细小皱纹;③“白皮肤”雀斑;④痤疮后疤痕⑤色素减退…  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号